Analyst firms · Barclays · MRNA

Barclays MRNA price target and rating history

Moderna Inc. (MRNA) · Health Care

Barclays rates Moderna Inc. (MRNA) Equal Weight with a $25 price target, as of its latest action on Jan 28, 2026. It has published 4 rating actions on MRNA since August 2021, including 0 upgrades and 1 downgrade. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. Barclays's $25 is 56% below that.

Current rating
Equal Weight
Price target
$25
Median target, all firms
$57
Actions on MRNA
4

Barclays price target on MRNA

$463$244$2520222023202420252026
Barclays price target on MRNA, each point a stated target, August 2021 to January 2026.

Every Barclays rating on MRNA

How other firms rate MRNA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
William BlairMkt PerformOct 27, 2026
CitigroupSell$80Sep 30, 2026
Rothschild & Co RedburnSell$81Sep 3, 2026
Argus ResearchBuy$180Aug 28, 2026
Wolfe ResearchPeer PerformAug 25, 2026
BofA SecuritiesNeutralAug 19, 2026
BarclaysEqual Weight$25Jan 28, 2026
UBSNeutral$34Jan 7, 2026
JefferiesHold$30Dec 12, 2025

Questions about Barclays and MRNA

What is Barclays's price target for MRNA?
Barclays's latest stated price target for Moderna Inc. (MRNA) is $25, from its action on Jan 28, 2026.
What is Barclays's rating on MRNA?
Barclays rates MRNA Equal Weight, a neutral rating, as of Jan 28, 2026.
When did Barclays last change its view on MRNA?
On Jan 28, 2026, Barclays resumes coverage at Equal Weight, price target $25.
How does Barclays's MRNA target compare with other analysts?
Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. Barclays's $25 is 56% below that.

More MRNA rating histories

All Barclays ratingsMRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.